Immune Modulation With PRaG-1 Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

May 26, 2026

Study Completion Date

June 26, 2026

Conditions
CancerSolid Cancer
Interventions
DRUG

PRaG-1(cordycepin tablet)

"The PRaG-1 cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201."

All Listed Sponsors
lead

Second Affiliated Hospital of Soochow University

OTHER